Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-1.95% | -8.87% |
Nov. 10 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
Jul. 25 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
Manager | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 2018-08-31 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 2022-12-31 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 60 | 2014-12-31 |
Director | Title | Age | Since |
---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 45 | 2014-06-03 |
Eric Cornut
BRD | Director/Board Member | 68 | 2016-08-25 |
Günter von Au
CHM | Chairman | 74 | 2017-09-26 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-.--% | -1.95% | - | - | 5.73B | ||
+0.39% | +4.61% | +8.74% | +88.80% | 46.46B | ||
-0.52% | +2.59% | +25.71% | +91.74% | 27.59B | ||
+0.98% | -4.56% | +31.19% | - | 18.04B | ||
+0.52% | +0.24% | -1.76% | +36.88% | 13.58B | ||
-0.58% | -1.96% | -10.24% | +138.93% | 10.22B | ||
-.--% | +0.14% | - | - | 6.79B | ||
+0.30% | +0.30% | +30.23% | +103.39% | 5.59B | ||
-1.00% | -0.21% | -34.87% | -44.96% | 5.18B | ||
-0.77% | -0.58% | +11.00% | +44.82% | 5.13B | ||
Average | -0.07% | -0.32% | +7.50% | +65.66% | 14.43B | |
Weighted average by Cap. | +0.10% | +1.01% | +12.10% | +80.46% |
- Stock Market
- Equities
- SAZ Stock